Navigation Links
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
Date:2/25/2010

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation stat
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Resverlogix Completes Patient Recruitment for ASSERT Trial
2. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
3. Resverlogix Presenting at Biotech Showcase
4. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
5. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
6. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
7. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
8. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
9. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
10. Resverlogix Provides Quarterly Update
11. Resverlogix Board of Directors Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor management ... safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 ... Headquartered in Dallas, TX , ISN has additional offices in ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... 2010 The Association for Career and Technical Education ... Role in Worker Retraining" that describes how career and ... adults and providing them the skills needed to re-enter the ... not only focus on local employment needs, but are also ...
... - YM BioSciences Inc. (NYSE Amex: YMI ... that identifies and advances a diverse portfolio of promising ... that it has priced an underwritten public offering of ... of $1.60 per share. The Company expects ...
... a biopharmaceutical company developing novel therapies to treat autoimmune ... announced that it has initiated a Phase 1 clinical ... profiles of TRX518, a monoclonal antibody designed to enhance ... effectively attack cancer cells.   The Phase ...
Cached Biology Technology:ACTE Releases Issue Brief Outlining Critical Role CTE Plays in Worker Retraining 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... of most public forests in Oregon and Washington more than ... U.S. Forest Service Pacific,s Northwest (PNW) Research Station has found. ... at the fringes of public forests, is the first to ... after the enactment of land use laws. The findings are ...
... The second annual Epigenetic Control and Cellular Plasticity ... remodeling contribute to various processes that lead to cellular ... 12-13, at the At the Beckman Center of the ... INFORMATION: Media planning to attend should ...
... Hospital have contributed to the development of a new ... the heart muscle which can lead to heart enlargement ... system was published simultaneously on November 18 by the ... ( JACC ) and Global Heart, the journal of ...
Cached Biology News:Development near Oregon, Washington public forests 2Top scientists to present at Epigenetic Control and Cellular Plasticity symposium 2New classification system for cardiomyopathy 2New classification system for cardiomyopathy 3
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Biology Products: